InvestorsHub Logo
Followers 13
Posts 2494
Boards Moderated 0
Alias Born 02/04/2014

Re: None

Tuesday, 03/22/2022 8:22:33 AM

Tuesday, March 22, 2022 8:22:33 AM

Post# of 326
ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain



insert-text-here



https://www.obseva.com/pressrelease-detail/?pr=4921
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OBSV News